Allos AI today announced $5 million in seed financing led by Oxford Science Enterprises (OSE) to commercialize the industry's ...

Teva Pharmaceutical Industries (NYSE:TEVA), a global leader in generic and specialty medicines with a market capitalization of $24.93 billion, has been navigating a complex market landscape with a mix ...

Amneal Pharmaceuticals (NASDAQ:AMRX) used a presentation and Q&A session at the JPMorgan conference to outline its ongoing ...

Viatris remains a value play with low valuation and high free cash flow, but growth is hampered by legacy drug price erosion and lack of innovation. The company’s shift from small-molecule generics to ...

Generic drugmakers continue to navigate a challenging U.S. market defined by persistent price erosion, intense competition and structurally thin margins. While demand for generics remains steady, ...

Price erosion in several mature molecules has continued through 2025 and into early 2026 ...